{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T17:01:23Z","timestamp":1648832483706},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2008,8,6]],"date-time":"2008-08-06T00:00:00Z","timestamp":1217980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s00115-008-2461-y","type":"journal-article","created":{"date-parts":[[2008,8,4]],"date-time":"2008-08-04T07:53:07Z","timestamp":1217836387000},"page":"67-76","source":"Crossref","is-referenced-by-count":1,"title":["Immunglobuline in der Neurologie"],"prefix":"10.1007","volume":"79","author":[{"given":"S.","family":"Cursiefen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"M\u00e4urer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,6]]},"reference":[{"key":"2461_CR1","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","volume":"61","author":"Achiron","year":"2004","unstructured":"Achiron A, Kishner I, Sarova-Pinhas I et al. (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis. A randomized, double-blind, placebo-controlled trial. Arch Neurol 61: 1515\u20131520","journal-title":"Arch Neurol"},{"key":"2461_CR2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","volume":"251","author":"Achiron","year":"2004","unstructured":"Achiron A, Kishner I, Dolev M et al. (2004) Effect of intravenous immunoglobulin treatment on pregnancy and post-partum related relapses in multiple sclerosis. J Neurol 251: 1133\u20131137","journal-title":"J Neurol"},{"key":"2461_CR3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","volume":"47","author":"Bain","year":"1996","unstructured":"Bain PG, Motomura M, Newson-Davis J et al. (1996) Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47: 678\u2013683","journal-title":"Neurology"},{"key":"2461_CR4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"Basta","year":"1994","unstructured":"Basta M, Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94: 1729\u20131735","journal-title":"J Clin Invest"},{"key":"2461_CR5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","volume":"51","author":"Buchwald","year":"2002","unstructured":"Buchwald B, Ahangari R, Weishaupt A, Toyka KV (2002) Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrom. Ann Neurol 51: 673\u2013680","journal-title":"Ann Neurol"},{"key":"2461_CR6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A et al. (2002) Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46: 467\u2013474","journal-title":"Arthritis Rheum"},{"key":"2461_CR7","first-page":"1993","volume":"329","author":"Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Eng. J Med 329: 1993\u20132000","journal-title":"J Med"},{"key":"2461_CR8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J et al. (1997) Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 48: 712\u2013716","journal-title":"Neurology"},{"key":"2461_CR9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","volume":"22","author":"Dalakas","year":"1999","unstructured":"Dalakas MC (1999) Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle Nerve 22: 1479\u20131497","journal-title":"Muscle Nerve"},{"key":"2461_CR10","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","volume":"345","author":"Dalakas","year":"2001","unstructured":"Dalakas M, Fujii M, Li M et al. (2001) High-dose intravenous immune globulin for stiff person syndrome. N Engl J Med 345: 1870\u20131876","journal-title":"N Engl J Med"},{"key":"2461_CR11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"Dalakas","year":"2001","unstructured":"Dalakas M, Koffman B, Fujii M et al. (2001) A controlled study of IVIG combined with prednisone in the treatment of IBM. Neurology 56: 323\u2013327","journal-title":"Neurology"},{"key":"2461_CR12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1468-1331.2006.01552.x","volume":"14","author":"Farbu","year":"2007","unstructured":"Farbu E, Rekand T, Vik-Mo E et al. (2007) Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blind randomized controlled pilot study. Eur J Neurol 14: 60\u201365","journal-title":"Eur J Neurol"},{"key":"2461_CR13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0140-6736(96)09377-4","volume":"349","author":"Fazekas","year":"1997","unstructured":"Fazekas F, Deisenhammer F, Strasser-Fuchs S et al. (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349: 586\u2013587","journal-title":"Lancet"},{"key":"2461_CR14","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","volume":"55","author":"Federico","year":"2000","unstructured":"Federico P, Zochodne DW, Hahn AF et al. (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55: 1256\u20131262","journal-title":"Neurology"},{"key":"2461_CR15","unstructured":"Frazer JK, Capra JD (1999) Immunoglobulins: Structure and function. In: Paul WE (ed) Fundamental Immunology. Raven Press, New York, 37\u201374"},{"key":"2461_CR16","first-page":"CD002277","volume":"1","author":"Gajdos","year":"2008","unstructured":"Gajdos P, Chevret S, Toyka K (2008) Intravenous immunoglobulin for myasthenia gravis. Cochran Database Syst Rev 1: CD002277","journal-title":"Cochran Database Syst Rev"},{"key":"2461_CR17","unstructured":"Gold R, Toyka KV (2007) Immuntherapie neurologischer Erkrankungen. UNI-MED, Bremen"},{"key":"2461_CR18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(06)70447-1","volume":"5","author":"Gonzales","year":"2006","unstructured":"Gonzales H, Sunnerhgaen KS, Sj\u00f6berg I et al. (2006) Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 5: 493\u2013500","journal-title":"Lancet Neurol"},{"key":"2461_CR19","first-page":"586","volume":"341","author":"Guillain-Bar\u00e9-Syndrome","year":"1993","unstructured":"Guillain-Bar\u00e9-Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methylprednisolone in Guillain-Barr\u00e9-syndrome. Lancet 341: 586\u2013590","journal-title":"Lancet"},{"key":"2461_CR20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/1352458506075654","volume":"13","author":"Haas","year":"2007","unstructured":"Haas J, Hommes OR (2007) A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 13: 900\u2013908","journal-title":"Mult Scler"},{"key":"2461_CR21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","volume":"119","author":"Hahn","year":"1996","unstructured":"Hahn AF, Bolton CF, Zochodne D, Feasby TE (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119: 1067\u20131077","journal-title":"Brain"},{"key":"2461_CR22","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","volume":"364","author":"Hommes","year":"2004","unstructured":"Hommes OR, Sorensen PS, Fazekas F et al. (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364: 1149\u20131156","journal-title":"Lancet"},{"key":"2461_CR23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"Hughes","year":"1997","unstructured":"Hughes RAC, Swan AV, Cornblath DR et al. (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9-syndrome. Lancet 349: 225\u2013230","journal-title":"Lancet"},{"key":"2461_CR24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"Hughes","year":"2001","unstructured":"Hughes RAC, Bensa S, Willison H et al. (2001) Randomized controlled trial of intravenous immunoglobulin (IVIg) versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50: 195\u2013201","journal-title":"Ann Neurol"},{"key":"2461_CR25","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"Hughes","year":"2007","unstructured":"Hughes RAC, Swan AV, Raphael J-C et al. (2007) Immunotherapy for Guillain-Barr\u00e9-Syndrom: a systematic review. Brain 130: 2245\u20132257","journal-title":"Brain"},{"key":"2461_CR26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"Hughes","year":"2008","unstructured":"Hughes RAC, Donofrio P, Bril V et al. (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136\u2013144","journal-title":"Lancet Neurol"},{"key":"2461_CR27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"I","author":"Imbach","year":"1981","unstructured":"Imbach P, Barandun S, d\u2019Apuzzo V et al. (1981) High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet I: 1228\u20131231","journal-title":"Lancet"},{"key":"2461_CR28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.410400209","volume":"40","author":"Jacobs","year":"1996","unstructured":"Jacobs BC, van Doorn PA, Schmitz PI et al. (1996) Campylobacter jejuni infections and anti-GM 1 antibodies in Guillain-Barr\u00e9-syndrome. Ann Neurol 40: 181\u2013187","journal-title":"Ann Neurol"},{"key":"2461_CR29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/jnnp.55.1.60","volume":"55","author":"Jann","year":"1992","unstructured":"Jann S, Beretta S, Moggio et al. (1992) High-dose intravenous human immunoglobulins in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry 55: 60\u201362","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2461_CR30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"Kazatchkine","year":"2001","unstructured":"Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747\u2013755","journal-title":"N Engl J Med"},{"key":"2461_CR31","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","volume":"37","author":"Lee","year":"2008","unstructured":"Lee D-H, Linker RA, Paulus W et al. (2008) Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37: 406\u2013409","journal-title":"Muscle Nerve"},{"key":"2461_CR32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","volume":"124","author":"Leger","year":"2001","unstructured":"Leger JM, Chassande B, Musset L et al. (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double blind, placebo-controlled study. Brain 124: 145\u2013153","journal-title":"Brain"},{"key":"2461_CR33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","volume":"56","author":"Mendell","year":"2001","unstructured":"Mendell JR, Barohn RJ Freimer ML et al. (2001) Randomised controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56: 445\u2013449","journal-title":"Neurology"},{"key":"2461_CR34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/jnnp.63.6.765","volume":"63","author":"Meucci","year":"1997","unstructured":"Meucci N, Cappellari A, Barbieri S et al. (1997) Long term effect of intravenous immunoglobulins and oral cyclophosphamide in mulitfocal motor neuropathy. J Neurol Neurosurg Psychiatry 63: 765\u2013769","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2461_CR35","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.wnl.0000258673.31824.61","volume":"68","author":"Mori","year":"2007","unstructured":"Mori M, Kuwabara S, Fukutake T, Hattori T (2007) Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 68: 1144\u20131146","journal-title":"Neurology"},{"key":"2461_CR36","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.55.8.1135","volume":"55","author":"Noseworthy","year":"2000","unstructured":"Noseworthy JH, O\u2019Brien PC, Weinshenker BG et al. (2000) IV immunoglobulin does not reverse established weakness in MS. Neurology 55: 1135\u20131143","journal-title":"Neurology"},{"key":"2461_CR37","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","volume":"56","author":"Noseworthy","year":"2001","unstructured":"Noseworthy JH, O\u2019Brien PC, Petterson TM et al. (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56: 1514\u20131522","journal-title":"Neurology"},{"key":"2461_CR38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","volume":"71","author":"Raphael","year":"2001","unstructured":"Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC (2001) Intravenous immune globulins in patients with Guillain-Barr\u00e9-syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71: 235\u2013238","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2461_CR39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0022-510X(99)00317-2","volume":"173","author":"Rotta","year":"2000","unstructured":"Rotta FT, Sussman AT, Bradley WG et al. (2000) The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 173: 129\u2013139","journal-title":"J Neurol Sci"},{"key":"2461_CR40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1468-1331.2002.00501.x","volume":"9","author":"Sorensen","year":"2002","unstructured":"Sorensen PS, Fazekas F, Lee M (2002) intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9: 557\u2013563","journal-title":"Eur J Neurol"},{"key":"2461_CR41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archneur.56.6.661","volume":"56","author":"Stangel","year":"1999","unstructured":"Stangel M, Toyka KV, Gold R (1999) Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 56: 661\u2013663","journal-title":"Arch Neurol"},{"key":"2461_CR42","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00115-005-1935-4","volume":"76","author":"Stangel","year":"2005","unstructured":"Stangel M, Gold R (2005) Hochdosierte intraven\u00f6se Immunglobuline in der Behandlung der Multiplen Sklerose. Update \u00fcber neue Studien. Nervenarzt 76: 1267\u20131272","journal-title":"Nervenarzt"},{"key":"2461_CR43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1055\/s-2007-970910","volume":"34","author":"Stangel","year":"2007","unstructured":"Stangel M, Gold R (2007) Use of intravenous immunoglobulins in neurological diseases: An update. Akt Neurol 34: 342\u2013347","journal-title":"Akt Neurol"},{"key":"2461_CR44","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.WNL.0000110185.23464.A1","volume":"62","author":"Terenghi","year":"2004","unstructured":"Terenghi F, Cappellari A, Bersano A et al. (2004) How long ist IVIg effective in multifocal motor neuropathy? Neurology 62: 666\u2013668","journal-title":"Neurology"},{"key":"2461_CR45","unstructured":"Toyka KV, Hartung HP, Hohlfeld R (1987) Klinische Neuroimmunologie. Diagnostik, Pathophysiologie, Therapie. VCH Verlagsgesellschaft, Weinheim"},{"key":"2461_CR46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","volume":"59","author":"Van","year":"1995","unstructured":"Van den Berg LH, Kerkhoff H, Oey PL et al. (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59: 248\u2013252","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2461_CR47","doi-asserted-by":"crossref","unstructured":"Van Koningsveld R, Schmitz PI, Mech\u00e9 FG et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9-syndrome: randomised trial. Lancet 192\u2013196","DOI":"10.1016\/S0140-6736(03)15324-X"},{"key":"2461_CR48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"Walter","year":"2000","unstructured":"Walter MC, Lochm\u00fcller H, Toepfer M et al. (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo controlled study. J Neurol 247: 22\u201328","journal-title":"J Neurol"},{"key":"2461_CR49","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/1531-8249(200003)47:3<314::AID-ANA6>3.0.CO;2-C","volume":"47","author":"Yuki","year":"2000","unstructured":"Yuki N, Ang CW, Koga M et al. (2000) Clinical features and response to treatment in Guillain-Barr\u00e9-syndrome associated with antibodies to GM 1b ganglioside. Ann Neurol 47: 314\u2013321","journal-title":"Ann Neurol"},{"key":"2461_CR50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1351-5101.2003.00701.x","volume":"10","author":"YMcCrone","year":"2003","unstructured":"YMcCrone P, Chisholm D, Knapp M et al. (2003) Cost\u2013utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 10: 687\u2013694","journal-title":"Eur J Neurol"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-008-2461-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-008-2461-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-008-2461-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:08:32Z","timestamp":1558588112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-008-2461-y"}},"subtitle":["Aktuelle Datenlage"],"short-title":[],"issued":{"date-parts":[[2008,8,6]]},"references-count":50,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["2461"],"URL":"https:\/\/doi.org\/10.1007\/s00115-008-2461-y","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,6]]}}}